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Objective: CD20 expression was reported at different rates in patients with multiple
myeloma. The importance of this B-cell antigen for plasma cells is still unknown. This study
aimed to investigate CD20 expression of myeloma cells in bone marrow, and any relationship
between the stage of disease, isotype and clinical features.
Methods: Sixty-one patients who were admitted to the hematology clinic of the Adnan
Menderes Medical School with the diagnosis of multiple myeloma according to the crite-
ria  of the “International Myeloma Working Group” were enrolled in this study. Age, gender,
Durie–Salmon stage, history of autologous hematopoietic stem cell transplantation, and the
distribution pattern and positivity of CD20 expression on multiple myeloma cells in bone
marrow were evaluated. The Mann–Whitney U and chi-square tests were used for statistical
analysis with a p-value < 0.05 being accepted as statistically signiﬁcant.
Results: Thirty patients (48.9%) had positive scores for CD20 with the distribution pattern
being most likely interstitial in 55.6% of the cases. There was no statistically signiﬁcant dif-
ference between immunohistochemical positivity for CD20 expression on multiple myeloma
cells, immunoglobulin type, and the stage of disease.
Conclusion: The combination of immunohistochemical studies with ﬂow cytometry may
reveal the importance of CD20 positivity in patients with multiple myeloma more  clearly.©  2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
markers such as CD10, CD19, CD20 and CD22 may be related
1IntroductionMultiple myeloma (MM)  is a clonal B-cell malignancy char-
acterized by the accumulation of mature plasma cells in the
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to the prognosis of patients with MM. According to studies,
CD20 expression may be related to a poor prognosis, however
the prognostic signiﬁcance in patients with MM  needs further
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Figure 1 – clustered pattern of CD20-positive myeloma cells
in bone marrow.
Table 1 – Characteristic features of patients with
multiple myeloma (n = 61).
Variable
Gender (M/F) 30/31
Mean age (years) 64 ± 11
Durie–Salmon system stage (n)
I 14
II 4
III 43
Immunoglobulin type (n)
IgG 38
IgA 9
Other 6
Light chain 8
CD20 positivitya (n) 30
a Cut-off value of 10%.
Table 2 – Association between immunohistochemical
positivity for CD20 of myeloma cells and
immunoglobulin type and the stage of disease.
Immunohistochemical
positivity for CD20a
p-Value
Durie–Salmon system stage (n)
I 4
II 1 >0.05
III 25
Immunoglobulin type (n)
IgG 23
IgA 2 >0.05
Other 1rev bras hematol hem
nvestigation.1 CD20 is a phosphoprotein, which plays a role in
-cell development. There are few studies about immunohis-
ochemical evaluations of CD20 expression on myeloma cells
n MM.2–4 Robillard et al.2 reported 12 (18%) of 66 patients
ith CD20 expression. The expression of CD20 by myeloma
ells is heterogeneous, and can be detected only in 13–22%
f patients.3 The same study reported that disease stabiliza-
ion is seen in 50–57% of CD20+ patients over a period of 10–27
onths.3 Mateo et al.5 reported CD20 expression in 17% of
ll MM cases with most of them having only CD20+ plasma
ells. In recent years, studies have focused on surface anti-
ens due to the importance of targeted therapies. The role of
nti-CD20 therapy for MM  has yet to be clearly established.4
his study aimed to investigate CD20 expression on myeloma
ells in bone marrow and any relationship between the stage
f disease, isotype and clinical features.
ethods
ixty-one patients (31 male, 30 female, mean age 64 ± 11
ears) with MM were enrolled in this study. The distribu-
ion pattern and positivity of CD20 expression on myeloma
ells in bone marrow, age, gender, Durie–Salmon stage and
he history of autologous hematopoietic stem cell trans-
lantation were evaluated. Clinical characteristics and CD20
xpression were evaluated at the time of diagnosis. Immuno-
istochemical staining of CD38, CD138, Kappa/Lambda were
pplied to lysine coated slides. CD20 expression was deter-
ined by immunohistochemical staining of bone marrow
iopsies. Immunohistochemical analysis was performed by
he avidin–biotin complex method. B lymphocytes were evalu-
ted comparing immunohistochemical analysis of CD20 with
ematoxylin–eosin stain. The patients were evaluated for
D20 positivity using a cut-off value of 10%. We  could not com-
are immunohistochemistry with ﬂow cytometry to detect
D20 in myeloma cells. Statistical analysis (Mann–Whitney
 and chi-square tests) was performed using the Statisti-
al Package for the Social Sciences and a p-value <0.05 was
ccepted as statistically signiﬁcant.
esults
he immunoglobulin type was IgG heavy chain for 38 (62.3%)
atients with no patients having IgM myeloma. Forty-three
atients (70.5%) were stage 3 according to the Durie–Salmon
taging system and 11 patients had medical histories of
utologous hematopoietic stem cell transplantation. Thirty
atients (49.2%) had positive scores for CD20 with the distribu-
ion pattern being most likely interstitial in 55.6%. Although
he cut-off value for CD20 positivity was 10%, CD20 expres-
ion was detected in 28.7% of all cases using a cut-off value of
0%. The clustered pattern of CD20 positive myeloma cells is
hown in Figure 1. The characteristic features of patients with
ultiple myeloma are shown in Table 1. There was no statis-
ically signiﬁcant difference between immunohistochemical
ositivity for CD20 of myeloma cells, immunoglobulin type,
nd the stage of disease (p-value > 0.05) (Table 2).
Light chain 4
a Cut-off value of 10%.
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Discussion
Different stages of differentiation of the neoplastic clone may
cause heterogeneity in MM.  Cell surface antigens may be help-
ful to determine the antigenic phenotype. Similar results have
been reported for the heterogeneity of antigenic expression
of plasma cells using two techniques (immunoﬂuorescence
and immunohistochemistry) with the results drawing atten-
tion to the antigenic heterogeneity.6 The antigen expression
of myeloma cells is heterogeneous, and immunophenotype
impacts on clinical outcome in MM.7
CD20 is a transmembrane phosphoprotein that acts as a
calcium ion channel in the cell membrane, and plays a role
in B lymphocyte activation and its differentiation to plasma
cells. The importance of this B-cell antigen for plasma cells is
still unknown.8
Flow cytometry is an easy and commonly used method
to determine cell surface antigens. A panel including CD20
is recommended by the International Consensus Group to
determine plasma cell immunophenotype.9 The European
Myeloma  Network recommends a minimal panel including
CD19, and CD56 but prefers a panel that includes CD20, CD117,
CD28, CD27 to detect abnormal plasma cells.10 Robillard et al.2
reported CD20 expression in 12 of 66 patients with MM.  CD10,
CD20 and HLA-DR were weakly positive in less than one-
third of patients in a study consisting of 112 untreated MM
patients.6 Ngo et al.7 evaluated 107 MM patients and reported
the clinical impact of immunohistochemical markers in bone
marrow biopsy samples with 32% of them being positive for
CD20. Loss of CD20 expression during the disease course cor-
relates with signiﬁcant worsening both of overall survival and
event-free survival compared to the time of diagnosis.7 Grigo-
riadis et al.11 analyzed newly diagnosed plasma cell myeloma
with an aim of identifying clinicopathological features of CD20
in this disease and found that CD20+ plasma cells are not a
unique subset in myeloma. CD20 positivity was reported in
17% of all multiple myeloma patients.5 In the current study,
48.9% of the patients had positive scores for CD20 with a cut-
off value of 10% and 28.7% of the patients with a cut-off value
of 20%.
Cell morphology may be associated with CD20 positivity.
Histological type of plasma cells and prognosis were evalu-
ated in 674 patients with MM.  A signiﬁcant relationship was
reported between CD20 phenotype and mature cells, more
importantly with small plasma cells (lymphoplasmacytic).12
Both morphologies are characterized by low-grade malig-
nancy. A correlation has also been reported between small
mature plasma cells, CD20 and t(11.14) in patients with MM.2
In addition, there were statistically signiﬁcant differences in
the expression of CD20 between plasma cell leukemia and
MM with CD20 displaying higher reactivity in plasma cell
leukemia8; none of the patients in the current study had the
latter disease.
The CD20 antigen is a suitable target in the treat-
ment of lymphoma patients, but the use of monoclonal
antibodies to treat MM  is still controversial. The differ-
ences between these two malignancies are the heterogeneity
and the weak expression of CD20 on plasma cells. Thus,
CD20 positive MM and Non-Hodgkin’s lymphoma withr. 2 0 1 5;3 7(1):34–37
plasmacytoid differentiation should be treated as separate
entities.
The patients in this study had a M-protein peak in the
gamma zone by serum protein electrophoresis. There was no
splenomegaly or organomegaly. Some studies have reported
that about half the plasma cells have a morphologically lym-
phoplasmacytic appearance. Immunohistochemical studies
may be helpful in these cases. Cytoplasmic immunoglobulin
is usually positive, but not CD20 on plasma cells.13 The asso-
ciation between CD20 expression and small mature plasma
cell morphology was reported in the study of Robillard et al.2
The signiﬁcance of CD20 expression in MM patients is not well
understood yet.
The CD20 antigen is associated with shorter survival,
and may be a poor prognostic factor for MM.4,6,14 Accord-
ing to Grigoriadis et al.,11 CD20+ plasma cell myeloma cases
represent a heterogeneous disease and not a unique clinico-
pathological entity. However, the prognostic signiﬁcance of
CD20 expression in MM alone is unclear. The effect of other
markers of the disease is not known clearly.4,6
CD20+ MM cells occurred in three patterns in the study by
Quinn et al.4; the patterns were reported as follows: diffuse
(63%), interstitial (33%), and clustered (4%). The relationship
between pattern, isotype in bone marrow and CD20 positivity
has been reported in the literature.4 According to this study,
24 cases were positive for CD20, 62.5% with IgG heavy chain
and ten cases with lambda light chain. In the current study
38 (62.2%) patients had IgG heavy chain MM but no patients
had IgM myeloma. Moreover there was a higher positivity
for CD20 expression compared to the literature; according
to the cut-off value of 20%, 28.7% of the patients were posi-
tive.
The limitations of this study were the small number
of cases and the use of only one methodology, immuno-
histochemical analysis, to evaluate CD20 expression. The
prognostic signiﬁcance of CD20 positivity might be better
evaluated by combining ﬂow cytometry and immunohisto-
chemical analysis in larger cohorts.
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